linezolid oral / Generic mfg. - LARVOL DELTA

Case Report: Rare Community-Acquired Pneumonia with Concurrent Methicillin-Resistant Staphylococcus aureus and Cryptococcus neoformans Infection in an Immunocompetent Young Male. (PubMed, Infect Drug Resist) - "The patient showed significant improvement after treatment with oral linezolid (0.6 g twice daily) for 2 weeks and oral fluconazole (400 mg once daily) for 6 months. This case highlights that even immunocompetent individuals can simultaneously contract multiple community-acquired pathogens, while also underscoring the clinical utility of NTS in the early diagnosis of co-infections and detection of resistance genes."

Journal • Cough • Infectious Disease • Pneumonia • Respiratory Diseases

SUCCESSFUL SALVAGE OF A PERITONEAL DIALYSIS CATHETER IN A CASE OF NONTUBERCULOUS MYCOBACTERIAL INFECTION (ISN-WCN 2026) - "Despite topical gentamicin, the discharge worsened. On Day -8, ultrasound showed a peri-catheter hypoechoic area consistent with TI, a swab for culture was obtained, and oral cefaclor was started...Empiric therapy with linezolid, amikacin, and clarithromycin was started on Day 1...Current guidance highlights NTM among atypical causes of refractory ESI, encourages individualized salvage strategies including exit-site relocationConclusion In PD patients with refractory ESI/TI, clinicians should obtain early AFB cultures and species identification to guide management. Early exit-site revision/debridement with an oral dual regimen of clarithromycin and sitafloxacin can salvage the catheter and maintain PD when cardiac dysfunction and obesity limit alternatives, demonstrating a practicalt success where evidence remains limited."

Clinical • Nontuberculous mycobacteria • Cardiovascular • Genetic Disorders • Heart Failure • Hematological Disorders • Infectious Disease • Nontuberculous Mycobacterial Disease • Obesity • Respiratory Diseases • Thrombocytopenia

Linezolid-Induced Pancytopenia with Hyponatremia: A Case Report. (PubMed, Curr Drug Saf) - "Based on the World Health Organization-Uppsala Monitoring Centre (WHOUMC) causality assessment scale, the association between linezolid and pancytopenia with hyponatremia is considered probable in this case. This case report emphasizes that clinicians should be cautious, as these serious adverse effects can occur on re-exposure to linezolid, even if absent during previous use."

Journal • Cardiovascular • Dermatology • Heart Failure • Hematological Disorders • Thrombocytopenia

Linezolid-Associated Triad of Acute Pancreatitis, Lactic Acidosis, and Hypoglycemia: A Rare Case Report and Literature Review. (PubMed, Am J Case Rep) - "Clinicians should suspect linezolid-induced toxicity in patients presenting with new or unexplained gastrointestinal or metabolic symptoms during treatment. Early recognition and prompt discontinuation are necessary."

Journal • Review • Chronic Kidney Disease • Dyslipidemia • Gastroenterology • Hypertriglyceridemia • Hypoglycemia • Infectious Disease • Metabolic Disorders • Nephrology • Pain • Pancreatitis • Renal Disease • Respiratory Diseases

Effectiveness and safety of a shortened oral regimen for rifampicin- or multidrug-resistant TB. (PubMed, IJTLD Open) - "This 9-month oral regimen was effective and safe and improved patient-reported outcomes. These results support broader adoption in national TB programmes across Latin America and beyond."

Journal • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Innovating shorter, all-oral, precise, individualized treatment regimen for rifampicin-resistant tuberculosis (INSPIRE TB): study protocol for a pragmatic randomised controlled trial. (PubMed, BMC Infect Dis) - P3 | "Identifying safer and effective short regimens remains an obstacle for drug-resistant tuberculosis and more treatment options are needed to benefit patients from different countries and settings to reduce disease burden. The INSPIRE TB study hopes to provide robust evidence on various options of safer and effective 9-month oral regimens for RR-TB in China."

Journal • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

THE UNSEEN CULPRIT: OCCULT CARDIAC ABSCESS PRESENTING AS RECURRENT MRSA BACTEREMIA (ACC 2026) - "Case: A 56-year-old male with poorly controlled T2DM, first presented in October with MRSA bacteremia attributed to a diabetic foot ulcer, treated with amputation and 6 weeks of vancomycin...He underwent joint resection and completed 6 weeks of daptomycin, followed by oral doxycycline, with initial blood culture clearance... The patient's recurrent MRSA bacteremia was resolved through identification and surgical management of an occult cardiac abscess, with no further bacteremia noted after surgery and a final course of ceftaroline and linezolid therapy. Comprehensive multi-modality cardiac evaluation is critical in persistent MRSA infections even in the setting of negative TEE, highlighting the limitations of the latter in this case."

Cardiovascular • Immunology • Infectious Disease • Inflammation • Type 2 Diabetes Mellitus

When the Brown Recluse Strikes Back: Acute Generalized Exanthematous Pustulosis After Loxosceles Envenomation (AAD 2026) - "Treatment: In the emergency department, the patient received intravenous (IV) fluids, vancomycin, cefepime, and ondansetron. Due to lack of improvement, he was switched to IV ampicillin-sulbactam and oral linezolid. Acetaminophen and morphine sulfate were added to the medication regimen. On day eight, the patient received 40mg of oral prednisone and was discharged the following morning after significant improvement."

Hematological Disorders • Immunology • CRP • HP

Incidence and management of Coagulase-Negative Staphylococcal Peritonitis: A single-centre experience with intraperitoneal Urokinase (UKKW 2026) - "In 2 patients with a first relapse episode, Urokinase 100,000 units IP was used weekly along with 3 weeks of IP vancomycin and oral rifampicin...On the 3rd relapse, daily IP urokinase 100,000 units was used safely along with IP Daptomycin and oral linezolid (rifampicin resistance noted)... CNS peritonitis is a common causative agent for PD peritonitis in our cohort with medical cure rates mirroring other large cohort studies. Relapse and repeat infections especially in the presence of enterococcal infection is a major issue. Utilizing effective antibiotic therapy along with high dose urokinase as an adjunct can help eradicate biofilm and aid in maintaining or prolonging technique survival."

Clinical • Cardiovascular • Infectious Disease • Nephrology

Linezolid for Syphilis Pilot Study (clinicaltrials.gov) - P2 | N=24 | Active, not recruiting | Sponsor: University of Southern California | Trial completion date: Mar 2026 ➔ Aug 2026 | Trial primary completion date: Dec 2025 ➔ Aug 2026 | Recruiting ➔ Active, not recruiting

Enrollment closed • Trial completion date • Trial primary completion date • Infectious Disease • CD4

New Lungs, Old Foes: The Challenges of Resistant Infections Pre - and Post-Transplant in a Patient with Cystic Fibrosis (ISHLT 2026) - "The patient was initiated on intravenous (IV) imipenem-cilastatin-relebactam and IV colistin based on clinical improvement with this regimen during a prior exacerbation...Sputum cultures grew methicillin-susceptible Staphylococcus aureus and P. aeruginosa susceptible to cefiderocol...He was started on empiric therapy for rapid growing NTM infection with tedizolid, azithromycin, ethambutol, imipenem, moxifloxacin, and inhaled amikacin...Following availability of susceptibilities, the patient was discharged on IV amikacin, oral azithromycin, and oral omadacycline. Donor investigation revealed a healthy 19-year-old man who drowned in a chlorinated pool.Summary This case highlights a successful lung transplant in a CF patient with ongoing pan-drug-resistant Pseudomonas infection, complicated by a donor-derived polymicrobial NTM infection. Although rare, such infections can be effectively managed with thoughtfully selected antimicrobial therapy."

Clinical • Post-transplantation • Bronchiectasis • Cystic Fibrosis • Genetic Disorders • Immunology • Infectious Disease • Nontuberculous Mycobacterial Disease • Pulmonary Disease • Respiratory Diseases • Transplantation

One Culprit, Three Damage Pathways: Vancomycin's Nephrotoxic Puzzle (NKF-SCM 2026) - "METHODS/CASE SUMMARY A 68-year-old male with right total knee arthroplasty complicated by prosthetic joint infection, being treated with outpatient vancomycin and cefepime, presented to the emergency department with wound dehiscence...He underwent irrigation and debridement, and antibiotics were transitioned to Linezolid and Ceftazidime...A four-week oral prednisone taper was initiated, and he was discharged to complete this and intravenous cefazolin. The patient returned for repeat wound dehiscence but was continued on prednisone, and his Cr returned to normal 45 days following taper initiation. CONCLUSION This case highlights the risks of using Vancomycin in the outpatient setting without close monitoring, but also the various causes of vancomycin-induced acute kidney injury, including cast nephropathy, ATN and AIN so that causative medications can be withheld and prompt treatment can be initiated."

Acute Kidney Injury • Infectious Disease • Nephrology • Orthopedics • Renal Disease

Intradiscal linezolid (PP353) treatment for chronic low back pain associated with Modic change type 1: an international, first-in-human, randomised, sham procedure-controlled, double-blind, phase 1b clinical trial. (PubMed, EClinicalMedicine) - P1/2 | "Oral amoxicillin reduced pain and disability in patients with chronic Low Back Pain (cLBP) and vertebral endplate bone oedema (Modic changes type 1; MC1) in two randomised controlled trials (RCTs), providing evidence that cLBP with MC1 may be caused by a chronic bacterial infection of the disc...Two intradiscal administrations of PP353 are well tolerated and could be an effective and minimally invasive, day case therapy for patients with cLBP associated with MC1 or mixed MC1 and MC2. Persica Pharmaceuticals Ltd funded the trial and was responsible for the conceptualisation, overall design, collation of data, decision to publish and the first draft of the manuscript."

First-in-human • Journal • P1 data • Back Pain • Infectious Disease • Lumbar Back Pain • Musculoskeletal Pain • Pain

Drug-Resistant Tuberculous Meningitis (DR-TBM) in a Low-Incidence Setting: Two Cases and an Evidence Review Highlighting Key Advances and Knowledge Gaps in Clinical Management. (PubMed, Open Forum Infect Dis) - "Both patients were treated with multidrug regimens including bedaquiline, a nitroimidazole, cycloserine, and linezolid...There was discordance between phenotypic (susceptible) and genotypic (resistant) drug susceptibility testing for rifampin. After treatment, both patients had excellent clinical outcomes, with at least 12 months of post-treatment follow-up. These clinical cases provide an opportunity to explore the role of molecular diagnostics in the diagnosis of drug-resistant tuberculous meningitis, drug regimen selection in the era of novel oral regimens, and clinical decision-making in the setting of discordance between genotypic and phenotypic drug susceptibility testing."

Journal • CNS Disorders • Hematological Disorders • Infectious Disease • Pain • Psychiatry • Pulmonary Disease • Respiratory Diseases • Suicidal Ideation • Tuberculosis

Tailoring antitubercular therapy in a critically ill patient with abdominal tuberculosis. (PubMed, BMJ Case Rep) - "We used an initial antitubercular treatment with the combination of intravenous amikacin, linezolid and levofloxacin until intestinal function recovered. She was then transitioned to standard oral therapy with rifampicin, isoniazid, pyrazinamide and ethambutol, achieving full recovery. This case highlights the value of short-term parenteral antitubercular regimens as a bridge in critically ill patients with gastrointestinal compromise, underscoring the role of pharmacokinetic considerations and multidisciplinary care."

Journal • Critical care • Gastrointestinal Disorder • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Diagnosis and Therapeutic Challenges of Drug-Resistant Tuberculosis Infection After Kidney Transplantation: A Rare Case Report. (PubMed, Infect Drug Resist) - "The patient self-discontinued initial anti-TB therapy after one month, leading to relapse nine months later, with confirmed rifampicin resistant...The treatment was adjusted to an all-oral regimen including isoniazid, moxifloxacin, clofazimine, cycloserine, and bedaquiline, resulting in significant clinical and radiological improvement...Multidisciplinary collaboration is essential for balancing anti-tuberculosis efficacy with graft survival. Although novel agents such as bedaquiline offer promising options for salvage therapy, their administration in transplant recipients requires intensified monitoring for drug-drug interactions and adverse events."

Journal • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Transplantation • Tuberculosis

Treatment Outcomes and Drug-Related Adverse Events Across Four Short-Course RR-TB Regimens in South Africa: A Retrospective Analysis. (PubMed, Int J Infect Dis) - "Under programmatic conditions, the BPaL-L regimen achieved the highest treatment success while maintaining manageable safety profiles. These findings provide valuable evidence to guide patient management and support implementation of novel MDR/RR-TB regimens in high-burden settings."

Adverse events • Journal • Retrospective data • Hematological Disorders • Infectious Disease • Otorhinolaryngology • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Case Report: Nocardia farcinica infectious arthritis and myositis in an immunocompromised host: diagnostic and management challenges. (PubMed, Front Med (Lausanne)) - "Initial therapy with trimethoprim-sulfamethoxazole (TMP-SMX) and ceftriaxone was limited by renal impairment and gastrointestinal intolerance, and susceptibility testing indicated TMP-SMX resistance...Subsequently, therapy was changed to oral minocycline because of linezolid-induced bone marrow suppression and intolerance...When classic regimens are limited by adverse effects, susceptibility-guided alternative therapies can be effective. For localized infections refractory to medical management, multidisciplinary surgical intervention remains a critical component of care."

Journal • Diabetes • Immunology • Infectious Disease • Metabolic Disorders • Myositis • Pain • Renal Disease • Rheumatology

Early recognition and multidisciplinary care in a pediatric patient with acute infectious purpura fulminans due to MRSA: A rare case report. (PubMed, IDCases) - "The child was treated with intravenous vancomycin (15 mg/kg every 6 h) and linezolid (10 mg/kg every 8 h) for 4 weeks, heparin infusion (20 units/kg/hour), and supportive management, followed by oral rivaroxaban (1 mg/kg twice daily) for the next 6 months. Plastic surgery was consulted for gangrene. This case highlights the importance of early recognition, targeted antimicrobial therapy, and multidisciplinary management of PF secondary to MRSA infection in children."

Journal • CNS Disorders • Hematological Disorders • Hepatology • Infectious Disease • Pediatrics • Thrombocytopenia • CRP

Exploring the opportunity for therapeutic drug monitoring (TDM) and precision dose antimicrobials in an outpatient antimicrobial therapy (OPAT) service: a prospective observational study. (PubMed, J Antimicrob Chemother) - "We have demonstrated that drug monitoring is practicable in the OPAT setting of a large institution with no on-site analytical capability. Current dosage regimens result in acceptable PK-PD target attainment. Our findings provide an initial step towards supporting TDM in OPAT."

Journal • Observational data • Cardiovascular

Mycobacterium abscessus lumbar osteomyelitis: A rare and challenging case with review of literature. (PubMed, IDCases) - "He was initially treated with IV amikacin, IV meropenem, IV tigecycline, and oral linezolid...He was discharged on IV tigecycline, imipenem, amikacin, and oral linezolid, later transitioning to oral omadacycline, azithromycin, and linezolid (Table 1). This case illustrates the challenges of managing Mycobacterium abscessus (MAB) infections, which require a multi-drug approach due to intrinsic and acquired antibiotic resistance. Therapy should begin with in-vitro guided IV antibiotics and transition to oral drugs for the continuation phase, optimizing therapeutic efficacy and overcoming resistance mechanisms."

Journal • Back Pain • Infectious Disease • Inflammation • Musculoskeletal Pain • Nontuberculous Mycobacterial Disease • Pain

Pregnant women with MDR/RR-TB and the all-oral 6-month regimen: experiences from a patient series in South Africa. (PubMed, Clin Infect Dis) - "These limited data suggests that in pregnant women, the BDLLfx/BDLCfz regimens have improved treatment and pregnancy outcomes compared to prior regimens. However, there is a high prevalence of unfavourable infant outcomes."

Journal • Acute Respiratory Distress Syndrome • Hematological Disorders • Human Immunodeficiency Virus • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Relapse and Emergent Resistance With Novel Short-Course Regimens for Multidrug-Resistant Tuberculosis, United States, 2022-2024. (PubMed, Open Forum Infect Dis) - "Bedaquiline, pretomanid, and linezolid with or without moxifloxacin (BPaL/M) are recommended oral 6-month treatment regimens for multidrug- or rifampin-resistant (MDR/RR) tuberculosis (TB)...Despite the advent of shorter and better tolerated bedaquiline-based regimens, US clinicians continue to face challenges in managing drug-resistant TB. These data support the need for expert management of these patients beyond routine TB care, as well as the need for close monitoring and follow-up months after treatment completion."

Journal • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Cost-effectiveness of BPaL/BPaLM as compared to mixed standard of care bedaquiline containing regimen for MDR/RR-TB. (PubMed, Indian J Med Res) - "Background & objectives Current options for treating tuberculosis (TB) that is resistant to rifampicin (RR-TB) are limited and available regimens are often lengthy and poorly tolerated. However, following recent evidence from the TB PRACTECAL trial, countries are considering programmatic adoption of six-month, all-oral treatment regimen such as bedaquiline, pretomanid, linezolid (BPaL) and BPaL with moxifloxacin (BPaLM)...Interpretation & conclusions Our findings indicate that BPaL based regimens are likely to be cost-saving and more effective than the current mixed SoC in a range of settings. Countries should consider programmatic uptake of BPaL based regimens to treat MDR/RR-TB."

HEOR • Journal • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Efficacy and safety of an all-oral delamanid-containing regimen in the treatment of multidrug-resistant pulmonary tuberculosis complicated by extrapulmonary tuberculosis: Four case reports and review of the literature. (PubMed, J Clin Tuberc Other Mycobact Dis) - "Regimens combined DLM with bedaquiline (BDQ), linezolid (LZD), fluoroquinolones, and companion drugs for ≥ 15 months...These findings-representing China's first systematic report of this regimen for multisite EPTB, including the pediatric case-align with WHO guidance and suggest DLM's potential utility based on its extensive tissue penetration. Further validation in larger multicenter studies is warranted."

Journal • Infectious Disease • Pediatrics • Pulmonary Disease • Respiratory Diseases • Tuberculosis